Programs & Expertise

Programs

Disorder TypeDisorderPatent & PCT SubmittedClinical & Epid. StudiesPathway
Characterization
Current Status
CNS1001 – Early Autism Detection✔️✔️✔️FDA Breakthrough Designation granted
CNS1002 – Attention Deficit Hyperactive Disorder✔️✔️Enrollment ongoing
CNS1003 — Psychosis & schizophrenia✔️✔️Enrollment ongoing
CNS1004 – Lou Gehrig’s Disease✔️✔️✔️FDA submission   Q2 2022
GutIBS, Eosinophilic Esophagitis, Microbiome✔️Enrollment ongoing
CancerPediatric Cancer✔️Enrollment ongoing
Data ScienceGlobal biodynamics dataset✔️✔️✔️Prototype complete

Expertise

Linusbio Precision Exposome Medicine Program Follows the evolving precision medicine paradigm:

  • Patient group stratification, disease & patient phenotyping
  • Biomarker & diagnostics, patient-journey monitoring
  • Characterization of pathways and biological mechanisms for target discovery
  • Drug development and clinical-trial design

near-future deliverables for neurodevelopmental disease:

  • First-in-class StrandDx™-ASD biomarker & diagnostic for autism.
  • FDA Breakthrough Designation for ASD, awarded.
  • Market access & reimbursement program for deNovo in vitro diagnostic.

milestone collaborations achieved on two fronts:

  • ASD pharmaceutical / clinical trials for older ASD patients
  • Non-pharmaceutical / nutraceuticals for high-risk ASD infants

Next breakthrough programs:

  • Amyotrophic lateral sclerosis (ALS)
  • Inflammatory bowel disease (IBD)
  • Attention deficit hyperactive disorder (ADHD)
  • Psychosis/schizophrenia
  • Renal disease
  • Pediatric cancer